Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology, Inc.

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades.  Sana is building differentiated capabilities across the spectrum of cell and gene therapy. 
 
Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body.  We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders.
 
Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Over 8 million people worldwide are currently living with type 1 diabetes. At Sana, we’re advancing our hypoimmune platform for the potential treatment of this and other serious diseases. 

Check out The Economist article below highlighting promising preclinical diabetes data using our hypoimmune technology that were recently published in Cell Stem Cell.

https://lnkd.in/gRcYJtY9

Cancer prevention awareness is a key step towards a healthier future. Together, let's inspire change, promote healthy lifestyles, and drive advancements in cancer innovation to prevent and treat cancer. 

Learn more about cancer prevention here: https://lnkd.in/gT2vd6hZ

#CancerPrevention #BiotechInnovation #Cellengineering #CellTherapy

We are excited to share the publication of preclinical diabetes data in Cell Stem Cell. 
 
Published data demonstrate that transplantation of Sana’s engineered allogeneic, hypoimmune (HIP)-modified pancreatic islet cells provided lasting glucose control, enabling the achievement of exogenous insulin independence without immunosuppression in a diabetic non-human primate (NHP). 
 
These data underscore the diverse and vast potential of the hypoimmune platform to transform the diabetes treatment landscape and beyond. 
 
Read more here: https://lnkd.in/g589pFsJ

Today we announced the closing of an upsized $189M public offering. 
 
We would like to recognize the tremendous support from healthcare investors, as well as the significant interest from scientific and healthcare communities, as we collectively work to change the possible for patients. 

Read more here: https://lnkd.in/gmX_ZVnV

At Sana, we recognize first-hand the vital role women play in driving innovation and shaping the future of science and medicine. 

We are committed to continuing to break barriers, inspire the next generation, and build a more inclusive and diverse scientific community. 

#WomenInScience #GirlsInScience #BiotechInnovation #STEMdiversity

Sana welcomes the Year of the Wood Dragon, a revered symbol in Chinese culture embodying growth, prosperity, and good fortune. 

We Look forward to a year filled with creativity, innovation, and abundant opportunities. #LunarNewYear

At Sana, our focus on changing the possible for patients through engineered cells is matched by our commitment to bring awareness to cancer prevention and early detection. 

Join us in fostering awareness, driving innovation, and uniting against cancer. Together, we can make strides in both treatment and prevention. 
 
#WorldCancerDay #CellTherapy #CancerPrevention #EarlyDetection

Sana will be honoring Black History Month throughout the month of February through various events within our community. 

The Sana Pledge is a commitment to ending inequality for all, and a meaningful part of our effort is directed toward countering racism and supporting the Black community.

"The future never just happened. It was created." -- Mae Jemison

#BlackHistoryMonth

We are honored for another feature in BioSpace’s annual Hotbed Maps, representing the most thriving life science regions across the country. With three primary office locations, Sana will be featured in the #BioForest, #BiotechBay, and #Genetown maps. 

In each of our locations, employees are relentless in discovering therapies that shift the possible for patients. 

Learn more about Sana, our culture, and open positions here: https://sana.com/join-us/

#hiring #jobsatSana

Today we memorialize the millions of lives lost and honor those who survived the acts of the Holocaust. We must stand united against hatred and intolerance, ensuring such atrocities never happen again.
 
#HolocaustRemembranceDay

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue	3.92M -	10.17M 159.40%	17.91M 76.13%	27.73M 54.80%	30.86M 11.30%
gross profit	-3.92M -	-10.17M 159.40%	-17.91M 76.13%	-27.73M 54.80%	-30.86M 11.30%
selling and marketing expenses
general and administrative expenses	21.78M -	28.27M 29.82%	50.41M 78.32%	71.56M 41.96%
selling general and administrative expenses	21.78M -	28.27M 29.82%	50.41M 78.32%	71.56M 41.96%	73.30M 2.43%
research and development expenses	119.38M -	257.88M 116.02%	306.50M 18.85%	201.00M 34.42%	221.64M 10.27%
other expenses	-29K -	97K 434.48%	305K 214.43%	-674K 320.98%
cost and expenses	141.15M -	286.15M 102.72%	356.91M 24.73%	272.56M 23.63%	325.81M 19.53%
operating expenses	141.15M -	286.15M 102.72%	356.91M 24.73%	272.56M 23.63%	294.94M 8.21%
interest expense				-15.63M -
ebitda	-139.33M -	-286.15M 105.38%	-356.91M 24.73%	-272.56M 23.63%	-294.94M 8.21%
operating income	-141.15M -	-286.15M 102.72%	-356.91M 24.73%	-272.56M 23.63%	-325.81M 19.53%
depreciation and amortization	1.83M -	5.92M 224.26%	11.07M 86.96%	15.63M 41.15%	30.86M 97.54%
total other income expenses net	2.83M -	844K 70.15%	981K 16.23%	3.09M 214.78%	42.55M 1,277.91%
income before tax	-138.32M -	-285.31M 106.26%	-355.93M 24.75%	-269.48M 24.29%	-283.25M 5.11%
income tax expense	-7.55M -	-6.67M 11.65%	-11.75M 76.15%	-3.09M 73.71%
net income	-130.78M -	-278.64M 113.06%	-344.18M 23.52%	-266.39M 22.60%	-283.25M 6.33%
weighted average shs out	187.34M -	187.51M 0.09%	166.43M 11.24%	188.34M 13.17%	194.54M 3.29%
weighted average shs out dil	187.34M -	187.51M 0.09%	166.43M 11.24%	188.34M 13.17%	194.54M 3.29%
eps	-0.70 -	-1.49 112.86%	-2.07 38.93%	-1.41 31.88%	-1.46 3.55%
epsdiluted	-0.70 -	-1.49 112.86%	-2.07 38.93%	-1.41 31.88%	-1.46 3.55%

NASDAQ:SANA

Sana Biotechnology, Inc.

Last Close

6.05

26/07 20:00

Market Cap

1.15B

Beta: 0.62

Volume Today

1.34M

Avg: 1.19M

PE Ratio

−4.34

PFCF: −4.09

Preview